republic-os/legislation/us/states/il/103rd/sb-1774.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	CLINICAL TRIAL PARTICIPATION	Amends the Cancer Clinical Trial Participation Program Act. Changes the short title of the Act to the Clinical Trial Participation Program Act. Throughout the Act, replaces references to "cancer clinical trial" with references to "clinical trial" and makes conforming changes. Provides that "clinical trial" includes a voluntary research study conducted on people and designed to answer specific questions about the safety or effectiveness of a drug, vaccine, therapy, medical device, medical diagnostic, or new way of using an existing treatment to treat or diagnose a condition. Defines "condition". Makes other changes. Effective immediately.	us/states/il	Illinois General Assembly	103rd	SB 1774	Illinois SB 1774 (103rd)	bill		enacted	Adriane Johnson Camille Y. Lilly	3	37	4	2023-02-09	2023-06-30	openstates	ocd-bill/f19d7ddd-2269-42e3-915d-5735a60597de	https://beta.ilga.gov/Legislation/BillStatus?DocNum=1774&GAID=17&DocTypeID=SB&LegId=146592&SessionID=112	d0d9cbd82b675043c108ead8bf2af8bce8347de9a8b945dcef96739151cfea69	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-il

Illinois SB 1774 (103rd) — CLINICAL TRIAL PARTICIPATION

Amends the Cancer Clinical Trial Participation Program Act. Changes the short title of the Act to the Clinical Trial Participation Program Act. Throughout the Act, replaces references to "cancer clinical trial" with references to "clinical trial" and makes conforming changes. Provides that "clinical trial" includes a voluntary research study conducted on people and designed to answer specific questions about the safety or effectiveness of a drug, vaccine, therapy, medical device, medical diagnostic, or new way of using an existing treatment to treat or diagnose a condition. Defines "condition". Makes other changes. Effective immediately.

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

1. Introduced (filed) — source
2. Engrossed (committee substitute) — source
3. Enrolled (enrolled) — source

Votes

• Third Reading — 57–0 (pass) · lower
• Third Reading — 111–0 (pass) · lower
• Approp-Health & Human Services — 23–0 (pass) · lower
• Public Health — 7–0 (pass) · lower

Sponsors

• Adriane Johnson — primary (person)
• Camille Y. Lilly — primary (person)
• Cristina Castro — cosponsor (person)
• Edgar González, Jr. — cosponsor (person)
• Laura M. Murphy — cosponsor (person)
• Linda Holmes — cosponsor (person)
• Margaret Croke — cosponsor (person)
• Mary Edly-Allen — cosponsor (person)
• Paul Faraci — cosponsor (person)
• Sara Feigenholtz — cosponsor (person)
• Willie Preston — cosponsor (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2023-02-09 Filed with Secretary by Sen. Adriane Johnson filing
• 2023-02-09 First Reading reading-1
• 2023-02-09 Referred to Assignments
• 2023-02-15 Added as Co-Sponsor Sen. Laura M. Murphy
• 2023-02-21 Assigned to Public Health referral-committee
• 2023-02-27 Added as Co-Sponsor Sen. Linda Holmes
• 2023-03-03 Added as Co-Sponsor Sen. Paul Faraci
• 2023-03-07 Added as Co-Sponsor Sen. Cristina Castro
• 2023-03-08 Do Pass Public Health; 007-000-000
• 2023-03-08 Placed on Calendar Order of 2nd Reading March 9, 2023 reading-2
• 2023-03-08 Added as Co-Sponsor Sen. Willie Preston
• 2023-03-10 Second Reading reading-2
• 2023-03-10 Placed on Calendar Order of 3rd Reading March 21, 2023
• 2023-03-13 Added as Co-Sponsor Sen. Mary Edly-Allen
• 2023-03-23 Placed on Calendar Order of 3rd Reading ** March 24, 2023
• 2023-03-28 Added as Co-Sponsor Sen. Sara Feigenholtz
• 2023-03-29 Third Reading - Passed; 057-000-000 passage, reading-3
• 2023-03-30 Arrived in House introduction
• 2023-03-30 Chief House Sponsor Rep. Camille Y. Lilly
• 2023-03-30 First Reading reading-1
• 2023-03-30 Referred to Rules Committee
• 2023-04-18 Assigned to Appropriations-Health & Human Services Committee referral-committee
• 2023-04-26 Committee/Final Action Deadline Extended-9(b) May 19, 2023
• 2023-04-27 Added Alternate Chief Co-Sponsor Rep. Edgar González, Jr.
• 2023-05-03 Motion Filed to Suspend Rule 21 Human Services Committee; Rep. Robyn Gabel
• 2023-05-03 Motion to Suspend Rule 21 - Prevailed 071-040-000
• 2023-05-03 Added Alternate Co-Sponsor Rep. Margaret Croke
• 2023-05-04 Do Pass / Short Debate Appropriations-Health & Human Services Committee; 023-000-000
• 2023-05-04 Placed on Calendar 2nd Reading - Short Debate reading-2
• 2023-05-10 Second Reading - Short Debate reading-2
• 2023-05-10 Placed on Calendar Order of 3rd Reading - Short Debate
• 2023-05-11 Third Reading - Short Debate - Passed 111-000-000 passage, reading-3
• 2023-05-11 Passed Both Houses
• 2023-06-09 Sent to the Governor executive-receipt
• 2023-06-30 Governor Approved executive-signature
• 2023-06-30 Effective Date June 30, 2023
• 2023-06-30 Public Act . . . . . . . . . 103-0227 became-law

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/f19d7ddd-2269-42e3-915d-5735a60597de. Confidence: reported (aggregated from official Illinois legislature records).